Randomized comparison between diquafosol ophthalmic solution versus rebamipide ophthalmic suspension for dry eye after penetrating keratoplasty

Randomized comparison between diquafosol ophthalmic solution versus rebamipide ophthalmic suspension for dry eye after penetrating keratoplasty - Ocular surface after penetrating keratoplasty

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020871

Enrollment

Registered

2016-02-03

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dry eyes undergoing PK

Interventions

Diquafosol ophthalmic solution: 4 times a day, 4 week period. Rebamipide ophthalmic suspension: 4 times a day, 4 week period.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Follow-up period after PK was at least 6 months or more. Patients with mild to moderate dry eye based on the criteria of Japanese Dry Eye Society, 2006.

Exclusion criteria

Exclusion criteria: Patients with a prior or present rejection response. Patients with corneal calcification or infectious keratitis. Patients with persistent epithelial defect or severe dry eye

Design outcomes

Primary

Measure	Time frame
TBUT, fluorescein score, and DEQS before and after the treatment	—

Countries

Japan

Contacts

Public ContactHidnenaga Kobashi

University of Kitasato School of Medicine, Department of Ophthalmology

himon@hotmail.co.jp+81-42-778-8464

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026